脾氨肽口服溶液预防性治疗季节性过敏性鼻炎的效果和对免疫功能的影响

Abstract
Figure/Table
References (21)
Related Citation (14)

Download: PDF (490 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Objective To investigate the clinical effect of Spleen Aminopeptide Oral Solution (SAOS) in the prophylactic treatment of seasonal allergic rhinitis (AR) and its effect on immune function. Methods A total of 52 patients with seasonal AR who were treated in the Affiliated Hospital of Inner Mongolia Medical University from May 2015 to May 2019 were selected as the research objects, and they were divided into group A (n=20), group B (n=20) and group C(n=12) according to the random number table method. Patients in group A received SAOS alone, group B received both SAOS and Loratadine, group C received Loratadine alone. The three groups were given different preventive intervention before the onset of AR. The influence of different drugs on the symptoms, quality of life, combined medication and T helper lymphocyte (Th) subsets (Th1/Th2) cytokines of patients with seasonal AR were compared among the three groups. Results At 2 weeks of treatment, the total score and sub item score of rhino-conjunctivitis quality of life questionnaire (RQLQ) in group B were lower than those in group C, the differences were statistically significant (P＜0.05). At 4 weeks of treatment, the total symptom score of group B was lower than that of group C, the difference was statistically significant (P＜0.05). The total score and sub item score of RQLQ in group B were lower than those of group C, the differences were statistically significant (P＜0.05). At 12 weeks of treatment, the scores of nasal symptoms and emotional reactions of group B were lower than those of group C, and the nasal symptoms score of group A was lower than those of group C, the differences were statistically significant (P＜0.05). In the pollen peak period (4 and 8 weeks of medication), the score of combined medication of group B was lower than that of group A and group C, the differences were statistically significant (P＜0.05). Cytokine detection of Th1/Th2 showed that the levels of interleukin (IL)-2, interferon-γ (IFN-γ), IL-4, IL-10 in group A after treatment were higher than those before treatment, and the differences were statistically significant (P＜0.05). The levels of IL-2, IFN-γ, tumor necrosis factor-α(TNF-α), IL-4, IL-6, IL-10 in group B after treatment were higher than those before treatment, the differences were statistically significant (P＜0.05). The levels of IL-2, IFN-γ, IL-4, IL-10 in group C after treatment were higher than those before treatment, the differences were statistically significant (P＜0.05). There were no significant differences in the levels of cytokines among the three groups after treatment (P＞0.05). Conclusion The combination of SAOS and Loratadine in the prophylactic treatment of seasonal AR can effectively relieve the symptoms, improve the quality of life,and affect the expression of Th1/Th2 cytokine levels, the curative effect is remarkable.

Key words： Allergic rhinitis Seasonal Immunomodulators Spleen Aminopeptide Prophylactic treatment

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I18/97

[1]	储俊才，程雷.变应性鼻炎变应原免疫治疗新指南[J].中国中西医结合耳鼻咽喉科杂志，2018，26（3）：161-162.
[2]	中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组，中华医学会耳鼻咽喉头颈外科学分会鼻科学组.变应性鼻炎诊断和治疗指南（2015年，天津）[J].中华耳鼻咽喉头颈外科杂志，2016，51（1）：6-24.
[3]	安羽三，欧阳昱晖.季节性过敏性鼻炎的研究现状[J].中国耳鼻咽喉头颈外科，2020，27（4）：199-201.
[4]	侯红枝，郑艳秋.内蒙古中西部地区变应性鼻炎疑似患者变应原分布的分析[J].中国眼耳鼻喉科杂志，2019，19（1）：22-25.
[5]	Wang XY，Ma TT，Wang XY，et al.Prevalence of polleninduced allergic rhinitis with high pollen exposure in grasslands of northern China[J].Allergy，2018，73（6）：1232-1243.
[6]	马婷婷，庄严，石海云，等.内蒙古自治区草原地区儿童变应性鼻炎流行病学调查[J].中华耳鼻咽喉头颈外科杂志，2019，54（8）：571-575.
[7]	罗嘉莹，胡佳晴，陈钊.PM2.5 与变应性鼻炎患者生活质量相关性研究[J].临床耳鼻咽喉头颈外科杂志，2018，32（4）：295-297.
[8]	何平，金晓杰.季节性变应性鼻炎的预防性治疗临床观察[J].中国耳鼻咽喉颅底外科杂志，2017，23（1）：12-15.
[9]	Yonekura S，Okamoto Y，Yamamoto H，et al.Randomized double-blind study of prophylactic treatment with an antihistamine for seasonal allergic rhinitis[J].Int Arch Allergy Immunol，2013，162：71-78.
[10]	Haruna T，Kariya S，Higaki T，et al.Determining an appropriate time to start prophylactic treatment with intranasal corticosteroids in Japanese Cedar Pollinosis[J].Med Sci （Basel），2019，7（1）：11.
[12]	李丽莎，关凯，李俊达，等.季节性变应性鼻炎预防治疗对患者生活质量的影响及相关转录组学研究[J].中华预防医学杂志，2021，55（5）：606-612.
[13]	范愈燕，王大业，赵晟，等.季节性过敏性鼻炎预防性治疗的临床研究[J].中华中医药杂志，2018，33（9）：4244-4248.
[14]	国家食品药品监督管理局.国家食品药品监督管理局国家药品标准修订件[J].中国药品标准，2014，15（3）：211-240.
[11]	Otsuka H，Otsuka K，Matsune S，et al.Nasal symptoms reduction and decreased neutrophilia in Japanese Cedar Pollinosis with prophylactic treatment with a combination of Montelukast，Fexofenadine，and Fluticasone Nasal Spray[J].Am J Rhinol Allergy，2019，33（4）：369-377.
[15]	江雪，李建文，冯丽春，等.布地奈德联合脾氨肽治疗过敏性鼻炎哮喘综合征患儿的临床效果及对VCAM-1 和Tim-1 的影响[J].临床误诊误治杂志，2021，34（3）：25-30.
[16]	黄海忠，林国栋.脾氨肽口服液在儿童变态反应性疾病中的疗效观察[J].深圳中西医结合杂志，2017，27（21）：153-154.
[17]	张丽，郝现伟，王云茹，等.经面罩吸入糖皮质激素联合脾氨肽治疗过敏性鼻炎-哮喘综合征患儿的临床疗效分析[J].中国妇幼保健，2018，33（1）：102-104.
[18]	曹雪涛.医学免疫学[M].北京：人民卫生出版社，2017：106-107.
[19]	Cheng L，Chen JJ，Fu QL，et al.Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis[J].Allergy Asthma Immunol Res，2018，10（4）：300-353.
[20]	杨艳，薛征.Th1/Th2 平衡在CARAS 中的免疫学机制及诊疗新靶点[J].医学研究杂志，2020，49（10）：12-15.
[21]	郝现伟，闫哲，张丽，等.脾氨肽联合糖皮质激素对过敏性鼻炎-哮喘综合征患儿外周血Th1/Th2 细胞因子表达的影响[J].中国妇幼保健，2018，33（9）：2007-2009.